Search Results
Jun 07, 2026, 22:49 ET Unitree stellt H2 Plus vor, einen humanoiden Referenzroboter auf Basis des NVIDIA Isaac GR00T für die akademische Forschung
NVIDIA Isaac GR00T, der einen humanoiden Unitree H2-Roboter, Sharpa-Fünf-Finger-Hände für geschickte Handhabung, NVIDIA Jetson Thor für fortschrittliche Entscheidungsfindung und Steuerung sowie die neue NVIDIA Isaac GR00T-Entwicklungsplattform vereint.Die Entwicklungsplattform Isaac GR00T – die von
More news about: Unitree Robotics
Jun 07, 2026, 22:47 ET Unitree annonce H2 Plus, un robot humanoïde de référence NVIDIA Isaac GR00T pour la recherche universitaire
Isaac GR00T associant un robot humanoïde Unitree H2, des mains à cinq doigts Sharpa pour une manipulation dextre, la puce NVIDIA Jetson Thor pour un raisonnement et un contrôle avancés, et la nouvelle plateforme de développement NVIDIA Isaac GR00T.La plateforme de développement Isaac GR00T (qui va
More news about: Unitree Robotics
Jun 07, 2026, 22:12 ET "Ngày Khách hàng thương hiệu 67" lần thứ 10 của Dongfeng Liuzhou Motor thúc đẩy những hướng đi mới cho tăng trưởng toàn cầu
Tại sự kiện này, Dongfeng Motor Group đã công bố Nền tảng xe thương mại năng lượng mới T1 thế hệ tiếp theo. Là nền tảng tích hợp hydro-điện 1.000V thế hệ thứ tư đầu tiên của ngành được phát triển dựa trên các tình huống sử dụng thực tế, nền
More news about: Dongfeng Liuzhou Motor Co., Ltd.
Jun 07, 2026, 21:00 ET GIGABYTE、AI最適化映像とOLED自動保護機能でゲーミングモニター技術を進化
Technologyを搭載した改良版AI OLED CARE PROにより、OLEDの信頼性をさらに向上させています。AI OLED CARE PROを補完するのが、一体型ヒートパイプと先進的な放熱素材を採用した強化された放熱設計です。FO27Q28Gは、競合他社のフラッグシップモデルと比較して、T-Con温度を12%低減し、ピーク時の表面温度を5%低下させ、温度均一性を最大35%向上させます。FO27Q28Gを含む一部のモデルには、焼き付きに対する4年間の延長保証も適用されます。拡充されたTactical Features GIGABYTEは、Tactical
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET 技嘉以 AI 技術提升畫質表現與 OLED 面板保護，重塑電競螢幕顯示體驗
感測技術，可自動監測使用者在席狀態、環境光源與像素維護需求，透過自動離席偵測、環境光調節與自動像素維護等機制，降低面板烙印風險並提升長期使用穩定性。除了智慧感測技術外，AI OLED CARE PRO 更搭配整合式熱導管與先進導熱材料的強化散熱設計。以 FO27Q28G 為例，相較同級旗艦產品可降低 12% T-Con 溫度、降低 5% 面板表面峰值溫度，指定機種更提供長達 4 年 OLED 防烙印保固，進一步提升使用者對 OLED 電競螢幕長期使用的信心。擴展更多戰術功能技嘉同步擴展戰術功能陣容，新增 Tactical HUD 與 Tactical Crosshair。Tactical
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET GIGABYTE Advances Gaming Monitor Technologies with AI-optimized Visuals and Automatic OLED Protection
OLED CARE PRO is an enhanced thermal design featuring integrated heat pipes and advanced thermal materials. The FO27Q28G delivers a 12% reduction in T-Con temperature, a 5% lower peak surface temperature, and up to 35% better temperature uniformity compared to competing flagship models. Selected models,
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET GIGABYTE Advances Gaming Monitor Technologies with AI-optimized Visuals and Automatic OLED Protection
OLED CARE PRO is an enhanced thermal design featuring integrated heat pipes and advanced thermal materials. The FO27Q28G delivers a 12% reduction in T-Con temperature, a 5% lower peak surface temperature, and up to 35% better temperature uniformity compared to competing flagship models. Selected models,
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET GIGABYTE apresenta avanços em monitores gamer com recursos de inteligência artificial e proteção automática de painéis OLED
integrados e materiais avançados de dissipação de calor. No modelo FO27Q28G, essa arquitetura resulta em redução de 12% na temperatura do circuito T-Con, diminuição de 5% na temperatura de superfície e até 35% de melhoria na uniformidade térmica em comparação com modelos concorrentes topo de linha. Alguns
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET GIGABYTE impulsa las tecnologías de los monitores para juegos con imágenes optimizadas mediante IA y protección automática de OLED
térmico mejorado que incluye tubos de calor integrados y materiales térmicos avanzados. El FO27Q28G ofrece una reducción del 12 % en la temperatura del T-Con, una temperatura máxima de superficie 5 % más baja y una uniformidad de temperatura hasta 35 % superior en comparación con los modelos insignia de la
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET GIGABYTE impulsa las tecnologías de monitores gaming con imágenes optimizadas por IA y protección OLED automática
diseño térmico mejorado con tubos de calor integrados y materiales térmicos avanzados. El FO27Q28G ofrece una reducción del 12 % en la temperatura del T-Con, una temperatura superficial máxima un 5 % menor y una uniformidad de temperatura hasta un 35 % mejor en comparación con los modelos insignia de la
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET GIGABYTE fait progresser les technologies des écrans gaming à l'aide de visuels optimisés par IA et d'une protection automatique de l'OLED
conception thermique améliorée dotée de caloducs intégrés et de matériaux thermiques de pointe. Le FO27Q28G offre une réduction de la température du T-Con de 12 %, une température de surface maximale inférieure de 5 % et une uniformité de température jusqu'à 35 % supérieure à celle des modèles phares
More news about: GIGABYTE
Jun 07, 2026, 21:00 ET GIGABYTE nâng tầm công nghệ màn hình chơi game với hình ảnh được tối ưu bằng AI và bảo vệ OLED tự động
tản nhiệt được cải tiến với các ống dẫn nhiệt tích hợp cùng vật liệu tản nhiệt tiên tiến. Mẫu FO27Q28G mang đến mức giảm 12% nhiệt độ bộ điều khiển T-Con, giảm 5% nhiệt độ bề mặt cực đại và cải thiện tới 35% độ đồng đều nhiệt độ so với các mẫu flagship cạnh tranh. Một số mẫu được lựa chọn, bao gồm FO27Q28G,
More news about: GIGABYTE
Jun 07, 2026, 20:08 ET OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
Therapeutics Holdings Limited ( The "Company" or "Oricell") , announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration (NMPA) to proceed into a confirmatory Phase II clinical
More news about: Oricell Therapeutics Holdings Limited
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
significantly reduced T cell receptor (TCR) expression on the surface of primary T cells. In healthy donor and systemic lupus erythematosus patient donor CD4+ T cells, ATG-207 demonstrated potent induced regulatory T cell activity, as measured by FOXP3 expression. Proteomic profiling of primary T cells treated
More news about: Antengene Corporation Limited
Jun 07, 2026, 19:05 ET El décimo "67 Brand Customer Day" de Dongfeng Liuzhou Motor avanza en nuevas vías para el crecimiento global
En el evento, Dongfeng Motor Group presentó su plataforma de vehículos comerciales de nueva energía T1 de próxima generación. Como la primera plataforma integrada de hidrógeno y electricidad de 1.000 V de cuarta generación del sector desarrollada a través
More news about: Dongfeng Liuzhou Motor Co., Ltd.
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
comparators across three phase 3 trials in adults with type 2 diabetes (T2D)1-3Data from the REIMAGINE clinical development program, a series of phase 3 trials evaluating once-weekly CagriSema in adults with T2D across various stages of their disease, were presented at an
More news about: NOVO NORDISK INC.
Jun 07, 2026, 17:30 ET Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
REIMAGINE 1: CagriSema as Monotherapy for Drug-Naïve T2DVanita R. Aroda, MDSymposium: REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care
More news about: American Diabetes Association
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
773-636-4910 (media)Elissa Snook, 609-251-1407 (media)Casey Capparelli, 805-447-1746 (investors) REFERENCESEroglu T, Capone F, Schiattarella GG. The evolving landscape of cardiometabolic diseases. EBioMedicine. 2024 Nov;109:105447. doi: 10.1016/j.ebiom.2024.105447.
More news about: Amgen
Jun 07, 2026, 06:04 ET Dongfeng Liuzhou Motor's 10th "67 Brand Customer Day" Advancing New Pathways for Global Growth
At the event, Dongfeng Motor Group unveiled its next-generation T1 New Energy Commercial Vehicle Platform. As the industry's first fourth-generation 1,000V integrated hydrogen-electric platform developed through a scenario-driven
More news about: Dongfeng Liuzhou Motor Co., Ltd.
Jun 06, 2026, 19:35 ET Texas Southern University Expands Elite Flight Training Fleet with New Twin-Engine Aircraft
been around more than 50 years. But I will promise you we've done everything possible to elevate our program. We've dotted every 'I' and crossed every 'T' with what's necessary to become a top 10 university in aviation in the United States. This is one of the final pieces of the puzzle and we're elated."The
More news about: Texas Southern University
Jun 06, 2026, 14:30 ET Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
Patients with T2D (TRANSCEND-T2D-1)Harpreet Singh Bajaj, MD, MPHSymposium: Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1
More news about: American Diabetes Association
Jun 06, 2026, 14:30 ET Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
enrolled more than 5,800 participants with additional results anticipated over the next year.About TRANSCEND-T2D-1 and the TRANSCEND-T2D clinical trial programTRANSCEND-T2D-1 (NCT06354660) is a Phase 3, 40-week, randomized, double-blind, placebo-controlled study comparing the efficacy
More news about: Eli Lilly and Company
Jun 06, 2026, 11:57 ET /C O R R E C T I O N -- U.S. Postal Service/
More news about: U.S. Postal Service
Jun 06, 2026, 09:07 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
June 6, 2026 /PRNewswire/ -- Novo Nordisk today announced new real‑world evidence in adults with type 2 diabetes (T2D) treated with once‑weekly semaglutide 1 mg that examines how escalating to semaglutide 2 mg compares with switching to tirzepatide and supports patient
More news about: Novo Nordisk
Jun 06, 2026, 09:01 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
June 6, 2026 /PRNewswire/ -- Novo Nordisk today announced new real‑world evidence in adults with type 2 diabetes (T2D) treated with once‑weekly semaglutide 1 mg that examines how escalating to semaglutide 2 mg compares with switching to tirzepatide and supports patient
More news about: Novo Nordisk